Cargando…

The value of prebiopsy FDG-PET/CT in discriminating malignant from benign vertebral bone lesions in a predominantly oncologic population

PURPOSE: To determine the value of prebiopsy (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET)/computed tomography (CT) in discriminating malignant from benign vertebral bone lesions. MATERIALS AND METHODS: This retrospective study included 53 patients with 55 vertebral bone lesi...

Descripción completa

Detalles Bibliográficos
Autores principales: Loudini, Naila, Glaudemans, Andor W. J. M., Jutte, Paul C., Yakar, Derya, Kwee, Thomas C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360653/
https://www.ncbi.nlm.nih.gov/pubmed/32253470
http://dx.doi.org/10.1007/s00256-020-03426-8
_version_ 1783559254185082880
author Loudini, Naila
Glaudemans, Andor W. J. M.
Jutte, Paul C.
Yakar, Derya
Kwee, Thomas C.
author_facet Loudini, Naila
Glaudemans, Andor W. J. M.
Jutte, Paul C.
Yakar, Derya
Kwee, Thomas C.
author_sort Loudini, Naila
collection PubMed
description PURPOSE: To determine the value of prebiopsy (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET)/computed tomography (CT) in discriminating malignant from benign vertebral bone lesions. MATERIALS AND METHODS: This retrospective study included 53 patients with 55 vertebral bone lesions that underwent FDG-PET/CT before CT-guided biopsy. Pathologic examination of the biopsy sample and a minimum follow-up of 1 year were used as reference standard. RESULTS: Sensitivity, specificity, positive predictive value, and negative predictive value of visual FDG-PET analysis (with lesion FDG uptake higher than liver FDG uptake as threshold for malignancy) in discriminating malignant from benign vertebral bone lesions were 91.3% (42/46), 22.2% (2/9), 85.7% (42/49), and 33.3% (2/6), respectively. The semiquantitative FDG-PET metrics SUV(max) and SUV(peak) achieved areas under the receiver operating characteristics curve of 0.630 and 0.671, respectively. Malignant lesions demonstrated bone lysis more frequently than benign lesions (60.9% (28/46) vs. 22.2% (2/9)), and this difference was nearly significant (P = 0.064). All other clinical and conventional imaging characteristics (including patient age, gender, previous diagnosis of malignancy, bone pain, weight loss, any CT abnormality, sclerosis, cortical destruction, bone marrow replacement, associated extraosseous soft tissue mass, and accompanying vertebral height loss, multiple bone lesions on FDG-PET/CT, and suspicious extraosseous lesions on FDG-PET/CT) were not significantly different (P = 0.143 to 1.000). CONCLUSION: FDG-PET/CT may steer the diagnosis (particularly thanks to a relatively high PPV and value of semiquantitative measurements), but cannot always classify vertebral bone lesions as malignant or benign with sufficient certainty. In these cases, biopsy and/or follow-up remain necessary to establish a final diagnosis.
format Online
Article
Text
id pubmed-7360653
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-73606532020-07-16 The value of prebiopsy FDG-PET/CT in discriminating malignant from benign vertebral bone lesions in a predominantly oncologic population Loudini, Naila Glaudemans, Andor W. J. M. Jutte, Paul C. Yakar, Derya Kwee, Thomas C. Skeletal Radiol Scientific Article PURPOSE: To determine the value of prebiopsy (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET)/computed tomography (CT) in discriminating malignant from benign vertebral bone lesions. MATERIALS AND METHODS: This retrospective study included 53 patients with 55 vertebral bone lesions that underwent FDG-PET/CT before CT-guided biopsy. Pathologic examination of the biopsy sample and a minimum follow-up of 1 year were used as reference standard. RESULTS: Sensitivity, specificity, positive predictive value, and negative predictive value of visual FDG-PET analysis (with lesion FDG uptake higher than liver FDG uptake as threshold for malignancy) in discriminating malignant from benign vertebral bone lesions were 91.3% (42/46), 22.2% (2/9), 85.7% (42/49), and 33.3% (2/6), respectively. The semiquantitative FDG-PET metrics SUV(max) and SUV(peak) achieved areas under the receiver operating characteristics curve of 0.630 and 0.671, respectively. Malignant lesions demonstrated bone lysis more frequently than benign lesions (60.9% (28/46) vs. 22.2% (2/9)), and this difference was nearly significant (P = 0.064). All other clinical and conventional imaging characteristics (including patient age, gender, previous diagnosis of malignancy, bone pain, weight loss, any CT abnormality, sclerosis, cortical destruction, bone marrow replacement, associated extraosseous soft tissue mass, and accompanying vertebral height loss, multiple bone lesions on FDG-PET/CT, and suspicious extraosseous lesions on FDG-PET/CT) were not significantly different (P = 0.143 to 1.000). CONCLUSION: FDG-PET/CT may steer the diagnosis (particularly thanks to a relatively high PPV and value of semiquantitative measurements), but cannot always classify vertebral bone lesions as malignant or benign with sufficient certainty. In these cases, biopsy and/or follow-up remain necessary to establish a final diagnosis. Springer Berlin Heidelberg 2020-04-06 2020 /pmc/articles/PMC7360653/ /pubmed/32253470 http://dx.doi.org/10.1007/s00256-020-03426-8 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Scientific Article
Loudini, Naila
Glaudemans, Andor W. J. M.
Jutte, Paul C.
Yakar, Derya
Kwee, Thomas C.
The value of prebiopsy FDG-PET/CT in discriminating malignant from benign vertebral bone lesions in a predominantly oncologic population
title The value of prebiopsy FDG-PET/CT in discriminating malignant from benign vertebral bone lesions in a predominantly oncologic population
title_full The value of prebiopsy FDG-PET/CT in discriminating malignant from benign vertebral bone lesions in a predominantly oncologic population
title_fullStr The value of prebiopsy FDG-PET/CT in discriminating malignant from benign vertebral bone lesions in a predominantly oncologic population
title_full_unstemmed The value of prebiopsy FDG-PET/CT in discriminating malignant from benign vertebral bone lesions in a predominantly oncologic population
title_short The value of prebiopsy FDG-PET/CT in discriminating malignant from benign vertebral bone lesions in a predominantly oncologic population
title_sort value of prebiopsy fdg-pet/ct in discriminating malignant from benign vertebral bone lesions in a predominantly oncologic population
topic Scientific Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360653/
https://www.ncbi.nlm.nih.gov/pubmed/32253470
http://dx.doi.org/10.1007/s00256-020-03426-8
work_keys_str_mv AT loudininaila thevalueofprebiopsyfdgpetctindiscriminatingmalignantfrombenignvertebralbonelesionsinapredominantlyoncologicpopulation
AT glaudemansandorwjm thevalueofprebiopsyfdgpetctindiscriminatingmalignantfrombenignvertebralbonelesionsinapredominantlyoncologicpopulation
AT juttepaulc thevalueofprebiopsyfdgpetctindiscriminatingmalignantfrombenignvertebralbonelesionsinapredominantlyoncologicpopulation
AT yakarderya thevalueofprebiopsyfdgpetctindiscriminatingmalignantfrombenignvertebralbonelesionsinapredominantlyoncologicpopulation
AT kweethomasc thevalueofprebiopsyfdgpetctindiscriminatingmalignantfrombenignvertebralbonelesionsinapredominantlyoncologicpopulation
AT loudininaila valueofprebiopsyfdgpetctindiscriminatingmalignantfrombenignvertebralbonelesionsinapredominantlyoncologicpopulation
AT glaudemansandorwjm valueofprebiopsyfdgpetctindiscriminatingmalignantfrombenignvertebralbonelesionsinapredominantlyoncologicpopulation
AT juttepaulc valueofprebiopsyfdgpetctindiscriminatingmalignantfrombenignvertebralbonelesionsinapredominantlyoncologicpopulation
AT yakarderya valueofprebiopsyfdgpetctindiscriminatingmalignantfrombenignvertebralbonelesionsinapredominantlyoncologicpopulation
AT kweethomasc valueofprebiopsyfdgpetctindiscriminatingmalignantfrombenignvertebralbonelesionsinapredominantlyoncologicpopulation